CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
LY573636-sodiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00428610
NCT00428610Phase 2Completed
CompareCT.gov

A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer

Eli Lilly and Company·interventional·Posted Jan 30, 2007·Updated Apr 19, 2018

In Brief

A Phase 2 clinical trial evaluating LY573636-sodium for Ovarian Cancer and 2 related conditions. Completed, enrolled 103 participants across 8 sites in 3 countries.

Detailed Summary

The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
CountriesItaly, Russia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2007
Enrollment StartFeb 1, 2007
Primary CompletionFeb 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 19.4 years ago

Interventions

LY573636-sodiumdrug

LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.